<DOC>
	<DOCNO>NCT01592279</DOCNO>
	<brief_summary>The new incretin-based therapy offer appeal advantage exist drug . Aside glucose dependent insulin secretion proven glucose lower efficacy , concomitant beneficial effect , low risk hypoglycemia , inhibition glucagon secretion maintenance counter-regulatory mechanism , promotion weight loss , possible cardiovascular benefit ( improvement lipid profile , blood pressure , endothelial myocardial function ) . The glucose lowering effect result inhibition glucagon secretion gastric empty rate could clinical importance type 1 diabetes . The rationale behind use GLP-1 analogue treatment type 1 diabetes relies assumption drug , addition action insulin secretion glucose regulation , may effective preserve even expand β-cell mass . This class drug may represent entirely new approach treatment type 1 diabetes , focus protection preservation β-cells . These therapy opportunity interfere disease progression use early intervention , enough β-cell mass/ function still preserve restore . Hypothesis : GLP-1 analogue ( liraglutide ) improve glycemic control measure HbA1c uncontrolled type 1 diabetic patient . The investigator expect reduction 1 % HbA1C baseline .</brief_summary>
	<brief_title>GLP-1 Analogue Treatment Uncontrolled Type 1 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . HbA1C ≥ 8 screen qualification 2 . Not treated GLP1 analogue 1 . Moderate sever hypoglycemia 2 . Creatinin &gt; 2 3. amylase lipase &gt; 3xULN 4 . Calcitonin &gt; 10 pg/ml Stimulated Calcitonin &gt; 50 pg/ml woman 80 pg/ml men 5 . ALT AST &gt; 3X ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>